Abstract
Twenty-seven fully evaluable patients with advanced ovarian cancer and documented disease progression despite cytotoxic treatment were treated with mitozolomide (NCS-353451) 90 mg/m2 as a 1-h infusion once every 6 weeks. None of the patients responded, one had stabilization of disease for 4 months. Haema-tologic toxicity was the major side effect with a nadir or white blood cell counts around day 40. Two patients died with severe leukopenia and septic shock. We conclude that mitozolomide is not active in this poor-risk group of patients.
Original language | English |
---|---|
Pages (from-to) | 663-665 |
Number of pages | 3 |
Journal | Acta Oncologica |
Volume | 28 |
Issue number | 5 |
DOIs | |
Publication status | Published - 1989 |
Keywords
- Advanced ovarian cancer
- Mitozolomide
- Phase II study
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
- Hematology